ALSO NOTED: Lantibio touts cystic fibrosis data; Crucell gets funds for TB vaccine; and much more...

> Orphan Pharmaceuticals and Lantibio announced positive final results from their Phase II clinical study of Moli1901, an experimental compound to treat cystic fibrosis. Release

> Crucell will receive up to $5 million from Rockville, MD-based Aeras Global TB Vaccine Foundation to support the advanced development of the candidate AdVac-based tuberculosis vaccine. Release

> Perrigo is buying Qualis, which makes OTC products, for $12 million. Report

And Finally... A new study concludes that CT screening for lung cancer doesn't save lives and leaves patients vulnerable to unnecessary surgery. Report

Suggested Articles

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.

The reported requirements suggest a company is unlikely to have the data needed to support an EUA before the election in six weeks.  

Blocking tau appears to be just as fruitless as clearing amyloid buildup when it comes to helping Alzheimer’s disease patients.